ICD-10 code C61: Malignant neoplasm of the prostate

Key Takeaways

ICD-10 code C61 is the billable diagnosis code for malignant neoplasm of the prostate, covering active prostate cancer under ICD-10-CM range C60-C63.

After definitive treatment with no residual disease, switch to Z85.46 (personal history of malignant neoplasm of prostate), not C61, to avoid claim denials.

Metastatic prostate cancer requires C61 as the primary code plus secondary site codes such as C79.51 (bone) or C79.82 (genital organs), always sequencing C61 first.

Pabau’s claims management software and structured client records help oncology and men’s health practices document staging, treatment status, and hormone therapy accurately for clean claims.

ICD-10 code C61, malignant neoplasm of the prostate, is a billable ICD-10-CM diagnosis code for prostate cancer at the primary site. It sits within the C60-C63 range (malignant neoplasms of male genital organs) under the broader C00-D49 neoplasm chapter. The men’s health clinic software category is where this code appears most in practice management contexts, but C61 is relevant to any specialty that treats or monitors prostate malignancy, including urology, radiation oncology, and primary care.

The code descriptor covers carcinoma of the prostate regardless of histological subtype (adenocarcinoma, small cell, ductal), provided the malignancy is located at the prostate as the primary site. It does not distinguish by Gleason score, TNM stage, or Grade Group. Those clinical details belong in the physician’s documentation to support the code selection, not in the code itself.

C61 code details at a glance

The distinction between the C61 leaf node and the C61- header category matters. The header (C61-) is listed as non-billable in many code lookup tools because it is a category header; the leaf node C61 is the specific, billable code. Always report C61, not C61-, on claims.

When to use ICD-10 code C61

Use C61 when the patient has a confirmed, active diagnosis of prostate cancer and the malignancy is at the primary site. The code applies across all treatment phases: active surveillance, watchful waiting, ongoing radiation therapy, chemotherapy, hormone therapy, and surgical treatment where residual disease remains or has not yet been confirmed absent.

• Active surveillance: Patient has confirmed low-risk prostate cancer being monitored with PSA tests and periodic biopsy, no treatment initiated. Use C61.
• During treatment: Patient is receiving radiation, androgen deprivation therapy (ADT), or chemotherapy for active prostate cancer. Use C61 as the principal or primary diagnosis.
• Residual disease post-surgery: Following radical prostatectomy where pathology confirms positive margins or residual disease is documented. Use C61, not Z85.46.
• Biochemical recurrence: Rising PSA after definitive treatment with documented or suspected active malignancy. Document the clinical basis; C61 may apply if the treating physician documents active recurrence.
• Castrate-resistant prostate cancer: Disease progressing despite androgen deprivation. C61 remains the primary code; additional codes reflect the treatment context.

For patient care management that spans multiple providers and treatment phases, consistent code assignment across encounters reduces downstream billing discrepancies and supports continuity in care coordination records.

C61 vs. Z85.46: Post-treatment coding

This is the most common coding error in prostate cancer management. Many practices continue using C61 indefinitely after the patient completes definitive treatment, when the correct code switches to Z85.46 (personal history of malignant neoplasm of prostate). Using C61 after the cancer is no longer present creates claim confusion and may trigger medical necessity reviews.

The rule is straightforward in principle: when the prostate has been removed and there is no clinical or pathological evidence of residual or recurrent disease, Z85.46 is the correct code. Continuing to report C61 misrepresents the clinical status and can lead to inappropriate treatment authorizations or audit issues. For ICD-10 coding guidance on related oncology scenarios, the same active-versus-history distinction applies across cancer code families.

Related ICD-10 codes used with C61

Prostate cancer rarely codes in isolation. Most encounters require one or more additional codes to reflect metastatic sites, treatment history, or concurrent therapies. Knowing which secondary codes attach to C61, and in what sequence, prevents the most common claim rejections in oncology billing. The AAPC Codify ICD-10-CM lookup provides current crosswalk data for each of these codes. For context on how ICD-10 diagnostic codes are structured across different disease categories, the hierarchical logic is consistent throughout the classification system.

• C79.51 (Secondary malignant neoplasm of bone): The most common metastatic site for prostate cancer. Always reported as a secondary code after C61 when bone metastasis is confirmed.
• C79.52 (Secondary malignant neoplasm of bone marrow): Used when bone marrow involvement is documented alongside or separate from C79.51.
• C79.82 (Secondary malignant neoplasm of genital organs): Used when prostate cancer has spread to adjacent genital structures.
• Z85.46 (Personal history of malignant neoplasm of prostate): Replaces C61 after definitive treatment with no residual disease, as covered above.
• D07.5 (Carcinoma in situ of prostate): A distinct pre-invasive lesion. Do not use C61 for carcinoma in situ; D07.5 is the correct code.
• Z79.81 (Long-term (current) use of antiandrogens): Report additionally when the patient is on ongoing androgen deprivation therapy. The ICD-10-CM tabular list instructs “use additional code” for this scenario.
• N40.x (Benign prostatic hyperplasia): May appear on the same claim when BPH is a concurrent condition. Do not confuse with C61; they are distinct diagnoses.

Coding metastatic prostate cancer

When prostate cancer has spread to secondary sites, the sequencing rule is clear: C61 is always the primary (first-listed) code, and the secondary site codes follow. This sequencing reflects that the prostate is the primary site of origin, even when the metastatic disease drives the clinical encounter.

Bone metastasis is the most clinically significant secondary site in prostate cancer. According to the CDC/NCHS ICD-10-CM web tool, C79.51 is the standard code for secondary malignant neoplasm of bone and is the most frequently paired secondary code with C61 in Medicare claims data.

Sequencing example: Prostate cancer with bone metastasis

1. C61 (Malignant neoplasm of prostate) – primary site, sequence first
2. C79.51 (Secondary malignant neoplasm of bone) – metastatic site
3. Z79.81 (Long-term use of antiandrogens) – if ADT is ongoing

Never reverse this sequence. Listing C79.51 first signals to the payer that the bone is the primary site, which misrepresents the malignancy and can change the DRG grouping, the medical necessity determination, and the reimbursement amount.

Multiple metastatic sites

When prostate cancer has spread to both bone and other organs (bladder, lymph nodes, distant organs), report C61 first and then each secondary site code separately. The WHO ICD-10 browser describes the hierarchical logic governing primary-to-secondary sequencing across neoplasm categories. There is no limit on the number of secondary site codes that can accompany C61, provided each is clinically documented.

Struggling with prostate cancer claim denials?

Pabau's claims management tools help urology and oncology practices document staging, treatment status, and hormone therapy coding accurately – reducing errors before submission.

Book a demo

Documentation requirements for C61

The code C61 is only as defensible as the documentation behind it. CMS and payer auditors look for specific clinical elements in the record before accepting a malignancy code on a claim. Missing any of these creates exposure on retrospective review.

Practices using patient intake software can build prostate cancer-specific templates that prompt clinicians for all required documentation fields at point of care. Combining that with structured patient records ensures that staging data, treatment history, and current status are consistently captured and retrievable. For the kind of audit trail this requires, clinical coding documentation standards in other oncology contexts follow the same underlying CMS guidance.

• Confirmed diagnosis: Pathology report or biopsy result confirming malignancy. PSA elevation alone does not support C61.
• Histological type: Adenocarcinoma, small cell, neuroendocrine, or ductal subtype, where available.
• Gleason score or Grade Group: Documents disease severity; supports medical necessity for treatment choices billed alongside C61.
• TNM staging: At minimum, clinical or pathological stage should be documented to support treatment decisions and DRG assignment.
• Treatment status: Active treatment, active surveillance, watchful waiting, or post-definitive treatment. This determines C61 vs. Z85.46.
• Hormone therapy: If ADT or antiandrogen therapy is ongoing, document current medications to support Z79.81 as an additional code.
• Metastatic sites: Imaging findings (CT, MRI, bone scan) confirming secondary sites, to support C79.51, C79.52, or C79.82.

MS-DRG groupings and reimbursement for C61

Under MS-DRG v43.0, an inpatient stay for prostate cancer that includes an operating-room procedure such as radical prostatectomy groups into one of two surgical DRGs, depending on whether a complication or comorbidity (CC) or major complication or comorbidity (MCC) is present:

• DRG 715: Other male reproductive system O.R. procedures for malignancy with CC/MCC
• DRG 716: Other male reproductive system O.R. procedures for malignancy without CC/MCC

The CC/MCC distinction matters because DRG 715 carries a higher relative weight and therefore a higher Medicare base payment than DRG 716. Documenting and coding comorbidities accurately – not just the prostate cancer itself – directly affects inpatient reimbursement. A patient admitted for radical prostatectomy who also has hypertension, diabetes, or a documented surgical complication may qualify for DRG 715; failure to capture those comorbidities on the claim means the facility receives the lower DRG 716 rate. Note that DRGs 715 and 716 apply only when an O.R. procedure is performed; a non-surgical prostate cancer admission groups instead into MS-DRG 722-724 (malignancy, male reproductive system, with MCC, with CC, or without CC/MCC).

Using claims management workflows that flag missing secondary diagnoses before submission reduces this revenue leakage. Practices with compliance management tools integrated into their billing workflow are better positioned to catch CC/MCC documentation gaps at coding review, not after a remittance shortfall. HIPAA-compliant medical records practices also protect the audit trail that supports DRG assignment during external reviews.

Hormone therapy coding

Androgen deprivation therapy is a cornerstone treatment for intermediate- and high-risk prostate cancer, and the ICD-10-CM tabular list includes a “use additional code” instruction for ongoing antiandrogen use. When the patient is currently receiving ADT (LHRH agonists, LHRH antagonists, or antiandrogens such as enzalutamide or abiraterone), report Z79.81 alongside C61.

Z79.81 is specifically designated for long-term (current) use of antiandrogens. It is distinct from Z79.890, which covers hormone replacement therapy in other clinical contexts. Using Z79.890 for prostate cancer ADT is incorrect; the tabular instruction points specifically to Z79.81 for antiandrogen use. Per the CMS ICD-10-CM Official Guidelines, “use additional code” instructions are not optional: where the clinical scenario applies, the additional code should be reported.

Conclusion

Prostate cancer coding pivots on three decisions: whether the disease is still active (C61 vs. Z85.46), whether metastatic sites need secondary codes in the correct sequence, and whether hormone therapy warrants Z79.81. Getting any of these wrong generates denials, audit exposure, and inaccurate DRG assignments.

Pabau’s practice management tools give urology and men’s health practices the documentation structure and claims workflows to get C61 coding right at the point of care, not during a rework cycle. To see how Pabau supports accurate oncology billing, book a demo.

Continue your research

Need documentation templates for oncology encounters? Digital clinical forms covers how structured intake and clinical templates reduce documentation gaps at point of care.

Managing men’s health coding across multiple locations? Men’s health clinic software outlines the workflow and compliance features built for this specialty.

Looking for related oncology coding reference? Clinical coding documentation standards covers ICD-10 sequencing principles applicable across oncology and acute conditions.

Frequently Asked Questions